# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-053664
Filing Date
2022-04-29
Accepted
2022-04-29 16:36:58
Documents
5
Period of Report
2022-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2213754-1_def14a.htm | DEF 14A | 525264
2 | GRAPHIC | lg_protalix-4c.jpg | GRAPHIC | 14927
3 | GRAPHIC | sg_eyalrubin-bw.jpg | GRAPHIC | 4887
4 | GRAPHIC | tm2213754d1-px_page01bwlr.jpg | GRAPHIC | 419360
5 | GRAPHIC | tm2213754d1-px_page02bwlr.jpg | GRAPHIC | 617741
| Complete submission text file | 0001104659-22-053664.txt |  | 1982432

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 22876348
SIC: 2836 Biological Products, (No Diagnostic Substances)